INTROduCTION In same patients lipid profile disturbances persist during nephrotic syndrome remission.
renal disease. Other reports have failed to show any difference in frequencies of individual apoE haplotypes between the healthy and the nephrotic subjects. 10, 11 Clinical trials have demonstrated that in about half of the nephrotic cases lipid profile disturbances persist during remission, which due to their clinical outcomes worsens further prognosis. 12, 13 The aim of the study was to evaluate the specific genetic polymorphisms of selected proteins participating in meta bolism of lipoprotein, including ABCA1, CETP and apoE and to test the hypothesis that they are associated with sustained lipid abnormalities observed during remission of nephrotic syndrome.
PATIENTs ANd mEThOds
Overall 50 patients aged between 5.8 and 16.6 (mean age 10.45 ±3.04) years, including 12 cases of steroid-resistant and 38 of steroid-dependent nephrotic syndrome, were evaluated. Duration of the disease ranged from 2.6 to 13.8 (mean 7.09 ±2.88) years. In 46 patients lipid profile was evaluated during complete remission of at least 8 weeks' duration and in 4 patients during partial remission. Seven patients were treated with prednisone, 42 subjects received prednisone combined with cyclosporine (which was in 7 subjects substituted to mycophenolate mofetil), and one individual took angiotensin-converting enzyme inhibitor combined with angiotensin type 1 receptor blocker. Clinical characteristics of the patients are shown in TAbLE 1.
Blood samples were drawn after the 12-hour overnight fast.
Total cholesterol and triglyceride levels were assayed with enzymatic methods cholesterol oxidase phenol 4-aminoantipyrine (CHOD-PAP) using the Spin-Reack set. LDL-C and VLDL-C lipoproteins were separated by ultracentrifugation and chemical precipitation using polyvinyle sulphate, HDL-C was isolated by chemical precipitation in presence of ions magnesium with use of volframic acid, and then fractions of cholesterol were estimated. The oxidized LDL-C level was ameasured using an ELISA (Bio-Medica reagents). Lipoproteins apoA1 and apoB were assayed with INTROduCTION Dyslipoproteinemia is seen in the majority of patients with idiopathic nephrotic syndrome. The compensatory mechanism of increased hepatic synthesis of lipoproteins triggered by proteinuria is regarded as the major underlying cause. Proteinuria is an independent risk factor of cardiovascular complications. 1 Among secondary dyslipidemias reduced conversion of low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol (HDL-C) and abnormal distribution of subclass HDL have particularly unfavorable effect.
2 Adenosine triphosphate binding cassette transporter A1 (ABCA1) has a crucial role in regulating cellular amounts of cholesterol and oxysterols as well as modulating the serum HDL-C level. This protein is the major modulator of removal of HDL-C fraction and phospholipids from cell membranes. It facilitates binding of intracellular phospholipids and cholesterol to apolipoprotein A1 (apoA1) associated with HDL, which determines the cholesterol efflux from vascular walls.
3-5 Non-estrified fatty acids, present in LDL-C, facilitate activation of polymorphic serum cholesterol ester transfer protein (CETP), which determines the size of lipoprotein molecules and their susceptibility to the catabolic process. An increase in CETP activity promotes conversion of HDL2 to HDL3 with decreased affinity to apoA1. It also diminishes the incorporation of apoA1 to HDL molecules, increasing their renal clearance and leading to hyperlipoproteinemia. 6, 7 Extent and persistence of abnormalities in lipid profile might be associated with apolipoprotein E (apoE) deficiency which is related to apoE genetic polymorphism. A specific genetic variant accounts for a certain lipoprotein level. The presence of ε2 allele correlates with decreased cholesterol and increased triglyceride levels. ApoE deficiency facilitates LDL-C and very low-density lipoprotein (VLDL) accumulation in renal glomeruli and promotes proliferation of cells and mesangial matrix. 8, 9 There have been conflicting reports on associations between specific apoE variants and renal disease. Some investigators have suggested higher incidence of specific genotypes in patients with nephritic syndrome and end-stage 15 It consists in DNA genome amplification with a pair of starters, sense and nonsense primers, and subsequent digestion of the reaction product restriction enzyme Hha I, and next separation of restriction fragments by electrophoresis in 4% agarose gel with ethidine bromide. Heterozygotic genotypes were identified on the basis of the presence of restriction fragments specific to specific alleles. Three single nucleotide variants of guanine (G) > adenine (A) transition of the ABCA1 gene such as V771M, V825I i R1587K that determine the HDL-C plasma level were genotyped by the self-developed method, using the restriction enzyme Tail for determining polymorphism V771M, the restriction enzyme MboI for polymorphism V825I and the restriction enzyme Bgl II for R1587K polymorphism. Transition G to A in position 2310 cDNA ABCA1 caused substitution of valine to methionine in position 771 of the polypeptide chain of ABCA1 protein (polymorphism V771M-G2310A). Transition G to A in position 2472 cDNA caused substitution of valine to isoleucine in position 825 of the polypeptide chain of ABCA1 protein (polymorphism V825I-G2472A). Transition G to A in position 4759 of cDNA caused substitution of arginine to lysine in position 1587 of the polypeptide chain of ABCA1 protein (polymorphism R1587K-G4759A). A CETP gene polymorphism was determined similarly to ABCA1, with the amplification DNA genome method, using DNA amplification with a pair of starters for nucleotide restriction in position −629 and -38.
statistical analysis The medians of lipid profile para meters were compared with reference values and between groups, divided in terms of presence or absence of lipid abnormalities during remission. The correlations between specific genetic polymorphisms and lipid profile abnormalities were analyzed. The normality of variable distribution was tested with Kolmogorov-Smirnov and Shapiro-Wilk tests. As the variables were not normally distributed, comparison of medians between groups was performed with Mann-Whitney's test. Analysis of correlations (in the whole population) was performed with non-parametric ANOVA Kruskal-Wallis's test. The study protocol, including genetic and bio chemical assessment, was designed in adherence to the Declaration of Helsinki. Written informed consent was obtained from all parents and the adolescent patients older than 16 years of age. A protocol of bio chemical and genetic investigations was approved by the Ethical Committee of the Children's Health Center. the immunoturbidic method using the Orion-Diagnostica kits. Lipoprotein (a) and apoE were assayed with radioimmunodiffusion on agarose gel by using specific antibodies. Lecithine acetyltransferase was determined by the enzymatic method using the Wak -Chemie kit. Glutathione and glutathione peroxidase in isolated erythrocytes were measured by the spectrophotometric method using the Oxis assay.
The results were assessed in comparison with normal reference values coming from the evaluation of the healthy Warszawa population aged between 6 and 20, published previously by investigators from the Children's Memorial Health Institute.
14 In all subjects the following genetic polymorphisms were evaluated: -three non-synonymous single nucleotide polymorphisms variants REsuLTs Persistent lipid profile abnormalities were present in 37 of 50 (74%) patients during remission of nephrotic syndrome. Comparison and analysis of median values of the lipid para meters in dys-and normolipidemic patients are presented in TAbLE 2. Significantly higher values of the majority of para meters were observed in dyslipidemic patients. There was no significant difference between steroid-dependent and steroid-resistant cases in this term. The only significant difference was observed in serum albumin levels, which were lower in steroid-resistant patients (p = 0.028).
The number and distribution of specific gene polymorphisms of ABCA1 are presented was a non-significant trend (p = 0.067) in terms of association between the triglyceride level and R1587K genotype.
dIsCussION Reports on lipid profile in nephrotic patients consistently indicated that these abnormalities can also persist during remission. 13, 16 Therefore, genetic background of disturbances in the activity of specific receptors or proteins involved in lipid meta bolism are considered. 17 Among pathomechanims of such changes, hypoalbuminemia and the disturbed activity of hepatic LDL receptor have been listed. 18 Some reports have suggested an influence of genetic variants of apoE on lipid abnormalities. There are few clinical studies on the frequency of specific alleles. Some reports have suggested the association between specific genotypes and focal segmental glomerulosclerosis (FSGS). Atilla et al. showed that prevalence of ε2 allele and ε2/ε3 genotype is higher in children with steroid-resistant nephrotic syndrome and FSGS. 10 Oda et al. demonstrated higher prevalence of apoε2 alleles in patients with chronic renal failure. 8 In patients participating in the current study, as in the report by Brushi et al., apoε2 and apo ε4 alleles in subjects with FSGS were more frequent. 11 The apoε3 was the predominant allele in these patients. Available data indicate the influence of sequence variants in ABCA1 and CETP on the plasma lipoprotein level in the general population. 17 How ever, there are no reports concerning genetic polymorphisms of these proteins and its possible clinical relevance in nephrotic patients. The results of the present study do not confirm the existence of such correlations. Among the causes which might explain persistent dyslipidemia in these patients is chronic pharmacotherapy, including cyclosporine A and steroids, with their unfavorable lipid-related side-effects.
19-21 These drugs were administered to almost all studied patients during remission, which was sustained by such treatment.
Of note, the significant limitation of the current study was a small number of patients (n = 50), therefore this observation should be verified in a multi-center trial involving a substantially larger population. Due to high costs of genotyping, we were unable to enrol a larger control group which could serve for analysis of distribution of specific genotypes in the healthy population. Recruitment of such a group would increase the statistical power of the analysis, and enable the use of para metric tests.
The results indicate the need for lipid profile monitoring not only during relapse, but also during remission of nephrotic syndrome, and for considering initiation of hypolipemic management in patients with persistent disturbances.
CONCLusIONs Up to 74% of nephrotic patients demonstrated persistent abnormalities of lipid profile during remission of the disease.
Among the remaining 19 subjects (not showing this polymorphism) abnormal lipid profile was observed in 15 patients (78.9%).
The apo ε3ε3 genotype (most commonly present in the healthy population) was found in 35 (70%) patients. Abnormal lipid profile was observed in 26 (74.3%) of these patients. Data are presented in TAbLE 6 .
The summary of the data on incidence of specific polymorphisms in normo-and dyslipidemic patients are presented in TAbLE 7 .
The results of analysis (ANOVA) of correlations between all consecutive genotypes in the whole population (n = 50) and all the studied para meters of lipid profile are shown in Analysis of 50 patients did not confirm the significant impact of specific polymorphisms of genes coding selected proteins involved in lipoprotein meta bolism on persistent lipid profile abnormalities during remission of nephrotic syndrome. Abbreviations: ApoA1 - apolipoprotein A1, ApoB - apolipoprotein B, GPX - glutathione peroxidase, GSH - glutathione, HDL-C - HDL-cholesterol, LCAT - lecithine acyltransferase, LDL-C - LDL-cholesterol, oxy-LDL-C - oxidized LDL-cholesterol, TC - total cholesterol, TG - triglycerides, VLDL-C - VLDL-cholesterol
